TRAIN Toolkit

This Innovative Medicines Initiative (IMI) report demonstrates how the first projects launched by IMI made concrete improvements to pharmaceutical research and development (R&D); leveraging funding; creating new knowledge and tools; and...

Rare disease represents one of the most significant issues facing the medical community and health care providers worldwide, yet the majority of these disorders never emerge from their obscurity, drawing little attention from the medical...

The NF Preclinical Initiative (NFPI) represents one of the Children’s Tumor Foundation’s groundbreaking models of scientific collaboration. The NFPI is aimed at accelerating proof of concept testing of potential effective repurposed drugs...

IBD Plexus is a research and information exchange platform whose goal is to accelerate research and transform the care of patients with inflammatory bowel disease (IBD). IBD Plexus will unite clinicians, patients, academia, and industry to...

FasterCures initiated the Consortia-pedia project to better understand the breadth and scope of approaches that a wide range of consortia have adopted to bring together nontraditional partners with a shared R&D goal. The report Identifies...

Multi-stakeholder collaboration isn’t just the participation trophy of biomedical research and development (R&D), a nice way to make sure everyone feels included. No one organization or sector alone can bring a scientific discovery through...

This FAQ of the Bayh-Dole Act of 1980 is part of our TRAIN program's Foundation University Partnerships Toolkit. It defines the Bayh-Dole Act, explains what the Act says about ownership of inventions and technologies, what requirements it...

Each Venture Philanthropy transaction involves numerous complicated issues: governance, intellectual property ownership and licensing, termination, indemnification, and publication, among others, but the issue that encompasses the most...

This report is one in a series on legal issues of interest to non-profit organizations engaged in or thinking about Venture Philanthropy work. It discusses the beginnings of Venture Philanthropy in drug development, the importance of an...

Since 1989, Schaner & Lubitz, PLLC has closed many transactions for disease foundation clients in the field that has come to be known as Venture Philanthropy. Though each charity and transaction have unique aspects, there are some issues...